5/27/2025 - 10:08 AM EST - BriaCell Therapeutics Corp : Announced that Bria-OTS has cleared its safety evaluation in the Phase 1/2 monotherapy study and has now transitioned to dosing patients in combination with a checkpoint inhibitor (CPI). The first patient has been dosed in the checkpoint inhibitor combination cohort of the ongoing Phase 1/2 study of Bria-OTS (NCT06471673) in metastatic breast cancer. BriaCell Therapeutics Corp
shares T.BCT are trading down $0.25 at $4.19.
